Latest GLP-1 Pill Shows Promise in Diabetes Management, Offering Potential Alternative to Injections
A new oral medication, orforglipron, developed by Eli Lilly, has demonstrated superior efficacy in lowering blood sugar and promoting weight loss compared to Novo Nordisk’s Rybelsus in a recent head-to-head clinical trial involving individuals with type 2 diabetes. The findings, released February 26, 2026, suggest a potential advancement in diabetes treatment, offering patients a convenient pill-based option. While the results are encouraging, a higher incidence of side effects leading to treatment discontinuation was observed with orforglipron, a factor clinicians and patients will need to consider. This development arrives as competition intensifies in the GLP-1 receptor agonist market, with both Lilly and Novo Nordisk vying for dominance in the treatment of diabetes and obesity.
GLP-1 receptor agonists have develop into increasingly popular in recent years for their dual benefits of improving blood sugar control and aiding in weight management. These medications mimic the effects of the naturally occurring glucagon-like peptide-1 hormone, which plays a role in regulating appetite and insulin secretion. Currently, many GLP-1 medications are administered via injection, a barrier to adoption for some patients. The availability of oral options, like Rybelsus and potentially soon orforglipron, expands access and convenience. The study’s results are particularly noteworthy as Lilly anticipates a decision from the U.S. Food and Drug Administration (FDA) regarding orforglipron’s approval for obesity treatment this spring, adding another potential weapon in the fight against the global obesity epidemic.
Orforglipron Demonstrates Greater Efficacy in Key Metrics
The phase 3 clinical trial, involving nearly 1,700 adults with type 2 diabetes whose blood sugar was not adequately controlled with metformin, randomly assigned participants to receive either two different doses of orforglipron (12mg or 36mg) or two doses of semaglutide, the active ingredient in Rybelsus (7mg or 14mg). At the study’s outset, participants had an average A1C level of 8.3 percent, a measure of long-term blood sugar control. After one year, those taking the higher dose of orforglipron experienced an average reduction in A1C of 1.9 percent, compared to a 1.5 percent reduction in the group receiving the higher dose of oral semaglutide. This difference suggests a more potent effect of orforglipron on glycemic control.
Beyond blood sugar management, the study also revealed significant differences in weight loss. Participants on the 36mg dose of orforglipron lost an average of almost 18 pounds, representing approximately 8 percent of their initial body weight. In contrast, those on the higher dose of oral semaglutide lost an average of 11.5 pounds, or about 5 percent of their starting weight. “So on efficacy alone, orforglipron looks better,” stated Dr. Osama Hamdy, an associate professor at Harvard Medical School and medical director of the Obesity Clinical Program at the Joslin Diabetes Center in Boston. These findings underscore the potential of orforglipron to address both metabolic and weight-related health concerns.
Side Effects and Discontinuation Rates
While orforglipron demonstrated superior efficacy, the study also highlighted a potential drawback: a higher rate of side effects leading to treatment discontinuation. Common side effects associated with both medications included gastrointestinal issues such as nausea, diarrhea, vomiting, and indigestion. However, approximately 10 percent of patients taking the higher doses of orforglipron discontinued treatment due to these side effects, compared to about 5 percent in the semaglutide group. This difference suggests that a greater proportion of patients may experience intolerable side effects with orforglipron, potentially impacting long-term adherence.
Convenience and Flexibility: A Key Advantage of Orforglipron
One notable advantage of orforglipron over Rybelsus is its flexibility regarding timing with meals. Unlike Rybelsus, which requires administration first thing in the morning on an empty stomach with a small sip of water, followed by a 30-minute waiting period before consuming anything else, orforglipron can be taken without any dietary restrictions. This convenience could be particularly beneficial for patients taking multiple medications, as noted by Dr. Melanie Jay, a professor at the New York University Grossman School of Medicine and director of the NYU Langone Comprehensive Program on Obesity Research. “This makes orforglipron easier to take,” Dr. Jay explained. Dr. Marilyn Tan, a clinical professor at Stanford University School of Medicine, added that adhering to a strict medication schedule can be “cumbersome,” making orforglipron a more practical option for some individuals.
How GLP-1 Receptor Agonists Work
Both orforglipron and oral semaglutide belong to a class of medications known as GLP-1 (glucagon-like peptide-1) receptor agonists. These drugs work by mimicking the action of the naturally occurring GLP-1 hormone, which is released in the gut in response to food intake. By activating GLP-1 receptors, these medications stimulate insulin release, suppress glucagon secretion, leisurely gastric emptying, and promote a feeling of fullness, ultimately leading to improved blood sugar control and weight loss. The goal for adults with type 2 diabetes is generally to achieve an A1C level below 7 percent, and the study showed that both doses of orforglipron, as well as the higher dose of oral semaglutide, helped patients reach this target.
The mechanism of action of GLP-1 receptor agonists extends beyond glucose regulation. By influencing appetite and satiety, these medications can contribute to significant weight reduction, which in turn can further improve metabolic health. This dual effect makes them valuable tools in the management of both type 2 diabetes and obesity, conditions often intertwined and contributing to a range of cardiovascular and other health complications.
Regulatory Outlook and Future Availability
Eli Lilly has stated its intention to submit an application to the U.S. Food and Drug Administration (FDA) for approval of orforglipron as a treatment for type 2 diabetes “as soon as possible.” The company is also seeking FDA approval for orforglipron as an obesity treatment, with a decision anticipated this spring. If approved, orforglipron could provide a valuable new option for individuals struggling to manage their weight and blood sugar levels. The potential approval of orforglipron for both diabetes and obesity underscores the growing recognition of the interconnectedness of these conditions and the need for comprehensive treatment strategies.
The competitive landscape in the GLP-1 market is rapidly evolving. Novo Nordisk currently holds a dominant position with its injectable medications Ozempic and Wegovy, as well as the oral Rybelsus. However, the emergence of orforglipron and other potential competitors threatens to disrupt this dominance. The pricing and accessibility of these medications will be crucial factors in determining their widespread adoption and impact on public health. The recent struggles of Novo Nordisk’s stock, attributed to pricing pressures and increased competition, highlight the challenges facing pharmaceutical companies in this dynamic market.
The FDA’s decision regarding orforglipron’s approval for obesity is expected this spring. This decision will be closely watched by healthcare professionals and patients alike, as it could significantly expand the treatment options available for individuals struggling with obesity and related metabolic disorders.
Dr. Helena Fischer is Editor, Health, at World Today Journal.
Worth a look